Prospective observational study of biomarkers to predict efficacy after Pembrolizumab in patients with PD-L1 positive advanced non-small cell lung cancer.

Prospective observational study of biomarkers to predict efficacy after Pembrolizumab in patients with PD-L1 positive advanced non-small cell lung cancer. - Exploration of biomarker after Pembrolizumab in lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026793

Enrollment

Registered

2017-03-31

Start date

2017-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Candidate for administration of pembrolizumab with written informed consent

Exclusion criteria

Exclusion criteria: Judgement as exclusion by chief mdical physians having auto-immune diseases

Design outcomes

Primary

Measure	Time frame
To explore the pretictive biomarkers after and before Pembrolizumab using blood samples.	—

Countries

Japan

Contacts

Public ContactKyoichi Kaira

Gunma University Oncology Clinical Development

kkaira1970@yahoo.co.jp027-220-8222

Outcome results